Voltar
Artigo Acesso aberto Revisado por pares
BIBTEX RIS

Employing a systematic approach to biobanking and analyzing clinical and genetic data for advancing COVID-19 research

2021; Springer Nature; Volume: 29; Issue: 5 Linguagem: Inglês

10.1038/s41431-020-00793-7

ISSN

1476-5438

Autores

Sergio Daga, Chiara Fallerini, Margherita Baldassarri, Francesca Fava, Floriana Valentino, Gabriella Doddato, Elisa Benetti, Simone Furini, Annarita Giliberti, Rossella Tita, Sara Amitrano, Mirella Bruttini, Ilaria Meloni, Anna Maria Pinto, Francesco Raimondi, Alessandra Stella, Filippo Biscarini, Nicola Picchiotti, Marco Gori, Pietro Pinoli, Stefano Ceri, Maurizio Sanarico, Francis P. Crawley, Giovanni Birolo, Alessandra Renieri, Francesca Mari, Elisa Frullanti,

Tópico(s)

PARP inhibition in cancer therapy

Resumo

Within the GEN-COVID Multicenter Study, biospecimens from more than 1000 SARS-CoV-2 positive individuals have thus far been collected in the GEN-COVID Biobank (GCB). Sample types include whole blood, plasma, serum, leukocytes, and DNA. The GCB links samples to detailed clinical data available in the GEN-COVID Patient Registry (GCPR). It includes hospitalized patients (74.25%), broken down into intubated, treated by CPAP-biPAP, treated with O

Referência(s)